TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04917861

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1893
Description: Solution for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1893
Description: Solution for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1893
Description: Solution for injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride solution for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride solution for injection
Study: NCT05854667

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual plus Placebo
Description: Participants receive once daily Lisdexamfetamine matched placebo for 15 weeks, as well as treatment as usual at clinical site.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual plus Placebo plus Contingency Management
Description: Participants receive once daily Lisdexamfetamine matched placebo for 15 weeks, as well as treatment as usual at clinical site, and engagement-focused contingency management for 12 weeks, week 2-13.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual plus lisdexamfetamine (LDX-01)
Description: Participants receive once daily Lisdexamfetamine for 15 weeks, as well as treatment as usual at clinical site. Medication is provided in 3 phases:~Week 1 (Induction Phase): 100 mg (Day 1 and 2), 150 mg (Day 3 and 4), 200 mg (Day 5, 6 and 7) Weeks 2-13 (Maintenance Phase): 250 mg per day (or the maximum tolerated for each individual) and then will continue on the same daily dose Weeks 14-15 (Taper Phase): 150 mg (Week 14) and 50 mg (Week 15).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual plus lisdexamfetamine (LDX-01) plus Contingency Management
Description: Participants receive once daily Lisdexamfetamine for 15 weeks, as well as treatment as usual at clinical site. Medication is provided in 3 phases:~Week 1 (Induction Phase): 100 mg (Day 1 and 2), 150 mg (Day 3 and 4), 200 mg (Day 5, 6 and 7) Weeks 2-13 (Maintenance Phase): 250 mg per day (or the maximum tolerated for each individual) and then will continue on the same daily dose Weeks 14-15 (Taper Phase): 150 mg (Week 14) and 50 mg (Week 15). Engagement-focused contingency management will be provided for 12 weeks, Week 2-13.
Study: NCT06121401

Intervention type: DRUG
Group type: OTHER
Intervention: Olaparib
Description: Olaparib is considered the study treatment. Olaparib tablets will be taken at the dose of 300 mg (2 x 150 mg tablet) twice daily adding to bevacizumab at a dose of 15 mg per kilogram of body weight every 3 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: Bevacizumab will be taken at a dose of 15 mg per kilogram of body weight every 3 weeks
Study: NCT05295992

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Varian Ethos Adaptive Radiation Therapy
Description: Daily adaptive external beam radiation therapy delivered on Varian Ethos treatment system.
Study: NCT05262439

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New generation CPAP mask
Description: All participants entered into the study will be couriered a new generation ResMed mask system to be used with their own CPAP machine and in place of their own mask.
Study: NCT06038383

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group A - Intervention with Virtual Reality (VR)
Description: Group of people with kidney disease that performed VR intervention during hemodialysis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group B - Intervention with Stationary Bike (SB)
Description: Group of people with kidney disease that performed SB intervention during hemodialysis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group A - Intervention with Stationary Bike (SB) - Crossover
Description: Group of people with kidney disease that performed SB intervention during hemodialysis after the washout period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group B - Intervention with Virtual Reality (VR) - Crossover
Description: Group of people with kidney disease that performed VR intervention during hemodialysis after the washout period.
Study: NCT05828602

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Conventional treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TeleRehabilitation
Description: TeleRehabilitation
Study: NCT05221216

Intervention type: OTHER
Intervention: Collect data of medical record
Description: Collect data of medical record: plasma concentrations of cotrimoxazole, demographic data (age, weight, height), data on the use of an extra renal replacement therapy (RRT) (date, type, number of sessions and duration of extra renal replacement therapy (RRT))
Study: NCT06407947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chimeric antigen receptor modified T cells Infusion
Description: chimeric antigen receptor T cells
Study: NCT04939883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Carvedilol will be dispensed in a staggered and progressive manner, initially from 6.25 mg twice daily, then increased to 12.5 mg twice daily, until maximum dose of 25 mg twice daily or development of contraindications
Study: NCT05705492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Given PO
Study: NCT06489574

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thoracic epidural with fentanyl in patients undergoing thoracotomy surgery
Description: A thoracic epidural catheter will be inserted at the T6- T7 intervertebral space, with the patient in the sitting position with standard aseptic precautions using an 18-G Touhy needle via a midline or paramedian approach with a loss of resistance method. A test dose of 3 ml of 2% lignocaine with adrenaline 5 µ/ml will be administered.~For thoracic surgery the sensory dermatome blockade needs to cover the incision and intercostal drains and may extend from T4 to T8.~The epidural drug will be administered according to the group allocation over a period of 10 minutes as follows:~Group B:~Patients will receive 50 μg fentanyl in addition to 10 ml 0.125% bupivacaine followed by a continuous infusion (10 ml bupivacaine + 100 μg fentanyl + 38 ml saline with rate of 5 ml per hour).
Study: NCT06319235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP
Description: DUOFAG® is a phage cocktail (cutaneous liquid) manufactured by MB PHARMA s.r.o. and it contains bacteriophages active against Staphylococcus aureus and Pseudomonas aeruginosa.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Sodium Chloride Injection solution was manufactured by B. Braun Melsungen AG. Marketing authorization number assigned from the State Institute for drug control (Czech Republic): 76/847/92-B/C
Study: NCT05303597

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ultrasound-guided diagnostic nerve block with lidocaine
Description: Patients with a trigger point in the posterior iliac crest will be evaluated by a second physician and diagnostic nerve block will be performed ultrasound-guided with the preliminary diagnosis of superior cluneal nerve entrapment. General Electric LogiqP5 model ultrasound device will be used and lidocaine will be applied between the posterior iliac crest and thoracolumbar fascia, which is viewed under the guidance of ultrasonography, for diagnosis and treatment.
Study: NCT05067946

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GX-19N
Description: DNA vaccine expressing SARS-CoV-2 S-protein antigen including the Nucleocapsid protein (NP) antigen

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: GX-19N formulation buffer
Study: NCT06249490

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: routine rehabilitation treatment
Description: All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: routine rehabilitation treatment
Description: All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride Injection
Description: The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study: NCT04476420

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nigella sativa oil
Description: Using N.sativa oil as an alternative to conventional management will help us to find a treatment option which is non-invasive, cost effective, inexpensive, easy available and belongs to a natural source with almost no side effects.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone Valerate
Description: it is a conventionally used drug for treating OSMF
Study: NCT05705492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Given PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study: NCT04249219

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Viewing e-cigarette ads
Description: All participants will see the same e-cigarette ads presented in a random order.
Study: NCT06175117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: compound E Jiao Jiang(cEJJ)
Description: compound E Jiao Jiang(cEJJ)：20ml (1 bottle) at a time, 3 times a day, should be taken orally before morning, lunch and dinner.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: compound E Jiao Jiang(cEJJ) placebo
Description: compound E Jiao Jiang(cEJJ) placebo：20ml (1 bottle) at a time, 3 times a day, should be taken orally before morning, lunch and dinner.~ferrous succinate tablet：1 tablet at a time, 2 times a day, should be taken in the morning, after dinner or during meals.
Study: NCT04976595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natesto
Description: Nasal gel containing testosterone 11 mg/dose (5.5 mg/nostril) three times daily.
Study: NCT05712161

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DurAVRTM THV System
Description: The DurAVR™ Transcatheter Heart Valve (THV) is a balloon expandable transcatheter aortic valve
Study: NCT05562063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Daily administration of sotagliflozin (2x200 mg, PO, OD) for 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for 6 months.
Study: NCT06286514

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study
Study: NCT05763082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: roflumilast cream 0.3%
Description: test product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoryve
Description: Reference Listed Drug product

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT05367609

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Preoperative Genotyping
Description: Genotype based risk prediction and personalized pain management
Study: NCT00098163

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV vCP1521
Description: One 1-ml dose of HIV-1 vaccine administered after birth on or before Day 3 and at weeks 4, 8, and 12.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ALVAC HIV-1 vCP1521
Description: One 1-ml dose of HIV-1 vaccine placebo administered after birth on or before Day 3 and at Weeks 4, 8, and 12.
Study: NCT05531019

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Echinochrome A
Description: Dietary Supplement with Echinochroma A Simple randomized design, in this arm patients will take 6ml of a 0.025% Echinochroma A solution twice a day for 90 days. 3 mg of Echinochroma A will be consumed per day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Simple randomized design, in this arm patients will take 6ml of an fructose aqueous solution twice a day for 90 days with the same flavor as the treatment
Study: NCT05705492

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04780724

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxic gas mixture
Description: Gas mixture of 12% O2 and 88% N2 for five minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypercapnic and hypoxic gas mixture
Description: Gas mixture of 12% O2, 5% CO2, and 88% N2 for five minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SpO2 measurement
Description: Two SpO2 measuring devices are active simultaneously during measurement.
Study: NCT05705492

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04780724

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SpO2 measurement
Description: Two SpO2 measuring devices are active simultaneously during measurement.
Study: NCT04990206

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TranS-C
Description: TranS-C will be provided in eight weekly, one-on-one 50-minute sessions delivered remotely by two-way video conferencing. Each week will include goal setting and homework assignments which will be reviewed in the following session.~The sessions will include information on sleep and circadian rhythms, behavioral change and motivation, and goal setting. The topics covered in the sessions include establishing regular sleep-wake times, learning a wind-down route, learning a wake-up routine, improving daytime functioning, correcting unhelpful sleep-related beliefs, and maintenance of behavior change.
Study: NCT05399095

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supine positioning: 5 days
Description: Supine positioning for 5 days after DMEK

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supine positioning: 1 days
Description: Supine positioning for 1 days after DMEK
Study: NCT06400680

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spine Kinematic Assessment with Optoelectronic system
Description: All measurements will be obtained using an optoelectronic multicamera system for human motion analysis (with eight high-resolution cameras with infrared light and a sampling frequency of 100 Hz.~The experimental protocol require the positioning of markers (plastic spheres covered by reflecting film). Markers will be placed by clinical operators (physiotherapists with training in optoelectronic system for human motion analysis) after training and experience in recognition of the position of spinous and transversal processes, by manual identification.~During the data acquisition protocol, the subject perform five trial of walking barefoot on a 6 m distance at a self-selected normal-pace speed.~Every subject repeated this operations 2 times with 2 different operators.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spine Kinematic Assessment with Optoelectronic system
Description: All measurements will be obtained using an optoelectronic multicamera system for human motion analysis (with eight high-resolution cameras with infrared light and a sampling frequency of 100 Hz.~The experimental protocol require the positioning of markers (plastic spheres covered by reflecting film). Markers will be placed by clinical operators (physiotherapists with training in optoelectronic system for human motion analysis) after training and experience in recognition of the position of spinous and transversal processes, by manual identification.~During the data acquisition protocol, the subject perform five trial of walking barefoot on a 6 m distance at a self-selected normal-pace speed.~Every subject repeated this operations 2 times with 2 different operators.
Study: NCT05059912

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Humanized CD7 CAR-T cells
Description: Patients will receive infusion of CAR T-cells targeting CD7 to confirm the safety and efficacy of CD7 CAR T-Cells in CD7+ relapsed or refractory T cell lymphoma
Study: NCT04780698

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 RT-PCR Assay for Detection of COVID-19 Infection
Description: COVID-19 infection and antibody testing
Study: NCT05425849

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rose oil aromatherapy
Description: Aromatherapy refers to the medicinal or therapeutic use of essential oils absorbed through the skin or the olfactory system. The positive effects of social support, such as hand-holding, on anxiety and pain have been described

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rose oil aromatherapy
Description: Aromatherapy refers to the medicinal or therapeutic use of essential oils absorbed through the skin or the olfactory system. The positive effects of social support, such as hand-holding, on anxiety and pain have been described
Study: NCT05290909

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The protocol of blended and problem-based learning
Description: The protocol of blended and problem-based learnin: The online platforms used in this research are the school's iLMS platform, online digital learning, and online opinion exchange platform. It will use online resources (Google, open educational resources, YouTube copyrighted medical micro-movies, and audio-visual materials), and the theme will be elderly care or emerging Multimedia resources on infectious themes, as well as real-time interaction with kahoot or Slido electronic whiteboards, will be uploaded to the office3655The One website. Drive is provided by the school (the school account is used to store course resources) and the system of digital theoretical course concepts in advance. Broadcasting, video (such as: values and conflicts; ethics and morality; patient rights and responsibilities; nurses' rights and responsibilities; ethical theory; basic ethical principles; ethical dilemmas and ethical decision-making; etc.), pre-recorded and stored on the Internet Road platform iLMS.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The traditional problem-oriented teaching model
Description: The traditional problem-oriented teaching model: There will be two PBL case introductions throughout the semester, with face-to-face teaching in physical classrooms.
Study: NCT06281210

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Omission of surgical treatment
Description: Omission of surgery in patients with pCR after neoadjuvant chemotherapy and negative VABB biopsy
Study: NCT06109649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afamelanotide and NB-UVB Light
Description: Patients will receive combination of NB-UVB twice weekly and afamelanotide every 3 weeks for 20 weeks.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: NB-UVB Light
Description: Patients will receive NB-UVB light twice per week for 20 weeks.
Study: NCT05174949

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (high-definition)
Description: Three conditions (2 mA, 20 mins):~1. anodal stimulation over the ipsilesional primary motor cortex~2. cathodal one over the contralesional premotor cortex~3. Sham
Study: NCT04939883

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo in a presumed staggered and progressive manner similar to the intervention group. The placebo will ideally be maintained for up to 30 days after the end of chemotherapy.
Study: NCT05174949

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (high-definition)
Description: Three conditions (2 mA, 20 mins):~1. anodal stimulation over the ipsilesional primary motor cortex~2. cathodal one over the contralesional premotor cortex~3. Sham

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (high-definition)
Description: Three conditions (2 mA, 20 mins):~1. anodal stimulation over the ipsilesional primary motor cortex~2. cathodal one over the contralesional premotor cortex~3. Sham

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (high-definition)
Description: Three conditions (2 mA, 20 mins):~1. anodal stimulation over the ipsilesional primary motor cortex~2. cathodal one over the contralesional premotor cortex~3. Sham

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (high-definition)
Description: Three conditions (2 mA, 20 mins):~1. anodal stimulation over the ipsilesional primary motor cortex~2. cathodal one over the contralesional premotor cortex~3. Sham

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (high-definition)
Description: Three conditions (2 mA, 20 mins):~1. anodal stimulation over the ipsilesional primary motor cortex~2. cathodal one over the contralesional premotor cortex~3. Sham
Study: NCT05788276

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg Tab
Description: Dapagliflozin active tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo tablets
Study: NCT05417451

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: All participants will receive a semi-standardized acupuncture protocol (standardized points for pain, fatigue, depression, anxiety, sleep disturbance, with additional points for patient's particular pain location)